



Malmö 4 March 2024

PRESS RELEASE

Aptahem's CSO to present at Biologics World Nordics Conference

Aptahem's CSO Dr Luiza Jedlina has been invited to speak at the Biologics World Nordics conference in Copenhagen on 7 March 2024.

The title of the presentation is "*A Novel RNA Aptamer Targets Exosite 2 on Thrombin, Offering a Potential Treatment for Systemic Inflammation through a Unique Mechanism*". More about the conference is found [via this link](#).

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.